We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Source Bio. | SBS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 17.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 17.50 | 17.50 |
| Top Posts |
|---|
Posted at 08/10/2020 07:29 by bubbleandleek so, from what i can gather we will be looking at a £40m raise which will provide working cap and clean up the balance sheet leaving the company debt free. it has gained a leading position in the covid testing space and if what i hear is correct could lead to something in the region of £60-£80m of free cash flow over the next 2 years.... this is on a c£100m market cap!! i understand that Harwood Capital are not selling down any of their holding either which makes me feel very comfortable. the rest of the business is doing well and growing but the short term opportunity in the covid testing space bring's about all sorts of opportunities. trying to work out how to get a chance to get involved as a retail investor?! |
Posted at 18/8/2016 08:20 by bartdude Posting of Scheme Document18 August 2016 RECOMMENDED CASH OFFER FOR SOURCE BIOSCIENCE PLC BY SHERWOOD HOLDINGS LIMITED Posting of Scheme Document On 29 July 2016, the boards of directors of Source BioScience and Sherwood announced that they had reached agreement on the terms of a recommended cash offer under which Sherwood intends to acquire the entire issued and to be issued ordinary share capital of Source BioScience for 18 pence in cash per Scheme Share held. It was also announced that the Acquisition would be effected by means of a scheme of arrangement under Part 26 of the Act and include an Unlisted Securities Alternative. Further to that announcement, the boards of Source BioScience and Sherwood are pleased to announce that the Scheme Document relating to the Acquisition was posted yesterday to Source BioScience Shareholders. The Scheme Document contains, inter alia, the full terms and conditions of the Scheme, an explanatory statement pursuant to section 897 of the Act, the expected timetable of principal events and details of the actions to be taken by Source BioScience Shareholders. As described in the Scheme Document, to become Effective, the Scheme must be approved at the Court Meeting; special resolutions must be passed at the General Meeting; and the Scheme must subsequently be sanctioned and confirmed by the Court. Both the Court Meeting and the General Meeting will be held at 1 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire NG8 6PX on 9 September 2016 with the Court Meeting to commence at 10.00 a.m. and the General Meeting to commence at 10.10 a.m. (or as soon thereafter as the Court Meeting is concluded or adjourned). Notices of the Court Meeting and the General Meeting are set out in the Scheme Document. The Scheme Document, together with information incorporated into it by reference to another source, will be available free of charge, subject to any applicable restrictions relating to persons resident in Restricted Jurisdictions, on the investor section of Source BioScience's website at www.sourcebioscience The expected timetable of principal events is as follows: Event Time and/or date Latest time for lodging PINK Forms of Proxy/CREST Proxy instructions for the Court Meeting 10.00 a.m. on 7 September 20161 Latest time for lodging WHITE Forms of Proxy/CREST Proxy instructions for the General Meeting 10.10 a.m. on 7 September 2016 Voting Record Time for Court Meeting and General Meeting 6.30 p.m. on 7 September 20162 Court Meeting 10.00 a.m. on 9 September 2016 General Meeting 10.10 a.m. on 9 September 20163 The following dates are indicative only and are subject to change (please refer to note 5 below): Scheme Court Hearing 13 September 2016 Latest time for withdrawals of elections in respect of the Unlisted Securities Alternative 2.00 p.m. on 14 September 2016 Latest time for lodging YELLOW Forms of Election / settlement of TTE Instructions through CREST 6.00 p.m. on 14 September 2016 Last day for dealings in, registrations of transfers of and disablement in CREST of, Source BioScience Shares 14 September 20166 Scheme Record Time 6.00 p.m. on 14 September 2016 Effective Date 15 September 2016 De-listing of Source BioScience Shares 7.00 a.m. on the Business Day following the Effective Date Despatch of cheques and certificates in respect of Sherwood Share Units and crediting of CREST accounts for Cash Consideration due under the Scheme Within 14 days of the Effective Date4 Notes: 1. The pink Form of Proxy for the Court Meeting may, alternatively, be handed to Equiniti Limited or the Chairman of the Court Meeting before the start of the Court Meeting. However, it is requested that, if possible, pink Forms of Proxy be lodged at least 48 hours (excluding any part of such 48-hour period falling on a weekend or a public holiday in the UK) before the time appointed for the Court Meeting. 2. If either of the Meetings is adjourned, then the Voting Record Time for the relevant reconvened Meeting will be 6.30 p.m. on the date two days before the date set for the relevant reconvened Meeting. 3. If the Court Meeting has not been concluded or adjourned prior to the scheduled commencement of the General Meeting, the commencement of the General Meeting will be delayed until the Court Meeting has been concluded or adjourned. 4. The latest date for dispatch of the Cash Consideration and certificates in respect of the Sherwood Share Units is 14 days after the Effective Date. 5. These times and dates are indicative only and will depend, amongst other things, on the date upon which the Court sanctions the Scheme and the date on which the Conditions set out in Part III of the Scheme Document are satisfied or (if capable of waiver) waived. If any of the expected dates change, Source BioScience will, unless the Panel otherwise consents, give notice of the change by issuing an announcement through a Regulatory Information Service and/or sending a further circular to Source BioScience Shareholders. 6. Source BioScience Shares released, transferred or issued under the Source BioScience Share Option Schemes may be registered after this date. Source BioScience Shareholders should carefully read the Scheme Document in its entirety before making a decision with respect to the Scheme. Terms and expressions in this announcement shall, unless the context otherwise requires, have the same meanings as given to them in the Scheme Document. A copy of this announcement and the Scheme Document will be made available on the investor section of Source BioScience's website at www.sourcebioscience |
Posted at 01/8/2016 16:05 by peterz Bigman - surprised you may be but true all the same. Buying medical solutions since November 2000. Yes 2000. Cash outlay of £97K a lot of money. Thos that were in those days will know the story - . Yes SBS have done well in recent years for later investors. I have a very substantial loss. Thats it. |
Posted at 12/6/2016 12:22 by peterz It is hard to admire bright speculators when the outcome means significant loss to long term investors - and the company that has been receiving support in terms of shareholders cash does not have the business awareness to "see it coming". As you say they will be OK though.Having bought from 2000 onwards Did MLS shareholders ever get replacement SBS |
Posted at 27/3/2016 10:17 by buywell2 POST REMOVED |
Posted at 24/11/2015 09:53 by bartdude Nice to see big investors coming in and bulking up on their share points. |
Posted at 11/9/2015 15:59 by buywell2 Hello Diamond1 are you a SBS holder now ?Shares Mags read some advfn BB's methinks buywell3 29 Jul'15 - 08:23 - 3127 of 3213 0 0 A few thoughts Source Bioscience had a presence in Biocity prior to this latest acquisition From the Source Bioscience March 2015 results : 'Operational highlights • Overnight Service™ for DNA sequencing launched from new laboratories in Los Angeles, BioCity Scotland and Tramore, Ireland Presumably SBS had its eye on Select Pharma very soon after moving into Biocity if not before. The acquisition of Vindon Healthcare was questioned by many. Many investors sold up as they did not see the sense in acquiring a business that manufactured cold storage rooms. Vindon was located in Rochdale, a new SBS production facility involving Inverclyde products has now been recently located nearby in the same Kingsway business park which allows for future product expansion The latest Select Pharma acquisition also requires cold storage provision , not surprisingly one would imagine that Vindon units(now SBS owned) will be used in the future and most likely Select Pharma were already leasing some. It does not take much out of the box thinking to expect SBS to replicate this model in the USA in a year or two. The integration and replication of Select Pharma services at existing Source Bioscience USA facilities will surely come at some point soon, which will then enable greater market penetration particularly within the states concerned and the neighbouring states. SBS has now made many acquisitions, this will be the sixth Vindon was acquired by obtaining institutional cash at 9.5p , which was circa 23% discount on the circa 12.5p share price that SBS was trading at the time. Select Pharma , which is a private unlisted company , has been acquired using institutional cash at raised at a share price of 14p which was the share price at the time of the announcement Why is this ? Private investors have all but sold out now Over 90% of shares rested in the hands of existing institutional investors and SBS management BEFORE this acquisition After the acquisition this figure will rise to over 95% In short , there are hardly any shares left for PI's to trade. The next acquisition which I expect will come within 18 months to two years , will be similar to this one with just one difference I expect the cash raised next time will be at a premium to the SP why ? SBS turnover and profits for this year are already in the bag as there will be a whole years trading of Vindon products included PLUS there will be some numbers to add from Select Pharma , I now expect over £31.5m turnover ( just over a 20% 2014 rise )and this time over £3m profit, I don't expect too much in the way of charges/costs for the Select Pharma acquisition. Also has anyone noticed that the number of distributors selling SBS Life Sciences products and services has increased to 18 from a recent 13 some 6 months ago ? So a 2014 disappointing flat Life Sciences number should start heading north once more, plus Atlanta and the USA should start contributing. 2016 turnover and profits look set rise as there will be a whole year of Select Pharma turnover and profits to be added together with increased cross selling opportunities gained by SBS access to Select Pharma clients and vice versa plus there are no shares left so any new institution wanting a meaningful stake will have to pay for it. SBS management, though I give them a hard time of it sometimes, are proving to be able to deliver the goods. Their acquisition choices are coming good, have been bought at decent prices , the way that they are gelling together and each new one is helping the rest shows the plan is working. Controlled growth by acquisition is the name of the game SBS Market Cap is now over £50m , this might attract some new Institutions that have minimum market cap limits set for investment purposes. Within 4 years I expect to see Turnover of £50m which will help to do the same In short , SBS is starting to look like it might be another ABC dyor |
Posted at 12/8/2015 08:22 by buywell3 ....................With respect to the above post it goes without saying that the Pharma Biotech & Life Sciences sector is going to be the place to be invested as the $USD rises in value and other sectors suffer ie a rotation by investors out of unsafe sectors into safe sectors. Some sectors will be ok, but ony a couple , and I am not interested in those as they do not do beneficial work to aid the progress of better and more effective drugs or help stop animals from being used in drug manufacture/testing on cosmetics or health or household testing of chemical compounds and products. UK companies that are exposed in the USA to revenue generation are thus set to benefit by $USD strength. Especially those that saw it coming and purchased companies in the USA when the £GDP was much stronger. Companies that have already spent money to improve such companies are set to reap the benefits of a higher $USD as it translates back into £GDP on the balance sheet. The Vindon Healthcare acquisition gave SBS USA exposure. |
Posted at 29/7/2015 08:23 by buywell3 A few thoughtsSource Bioscience had a presence in Biocity prior to this latest acquisition From the Source Bioscience March 2015 results : 'Operational highlights • Overnight Service™ for DNA sequencing launched from new laboratories in Los Angeles, BioCity Scotland and Tramore, Ireland Presumably SBS had its eye on Select Pharma very soon after moving into Biocity if not before. The acquisition of Vindon Healthcare was questioned by many. Many investors sold up as they did not see the sense in acquiring a business that manufactured cold storage rooms. Vindon was located in Rochdale, a new SBS production facility involving Inverclyde products has now been recently located nearby in the same Kingsway business park which allows for future product expansion The latest Select Pharma acquisition also requires cold storage provision , not surprisingly one would imagine that Vindon units(now SBS owned) will be used in the future and most likely Select Pharma were already leasing some. It does not take much out of the box thinking to expect SBS to replicate this model in the USA in a year or two. The integration and replication of Select Pharma services at existing Source Bioscience USA facilities will surely come at some point soon, which will then enable greater market penetration particularly within the states concerned and the neighbouring states. SBS has now made many acquisitions, this will be the sixth Vindon was acquired by obtaining institutional cash at 9.5p , which was circa 23% discount on the circa 12.5p share price that SBS was trading at the time. Select Pharma , which is a private unlisted company , has been acquired using institutional cash at raised at a share price of 14p which was the share price at the time of the announcement Why is this ? Private investors have all but sold out now Over 90% of shares rested in the hands of existing institutional investors and SBS management BEFORE this acquisition After the acquisition this figure will rise to over 95% In short , there are hardly any shares left for PI's to trade. The next acquisition which I expect will come within 18 months to two years , will be similar to this one with just one difference I expect the cash raised next time will be at a premium to the SP why ? SBS turnover and profits for this year are already in the bag as there will be a whole years trading of Vindon products included PLUS there will be some numbers to add from Select Pharma , I now expect over £31.5m turnover ( just over a 20% 2014 rise )and this time over £3m profit, I don't expect too much in the way of charges/costs for the Select Pharma acquisition. Also has anyone noticed that the number of distributors selling SBS Life Sciences products and services has increased to 18 from a recent 13 some 6 months ago ? So a 2014 disappointing flat Life Sciences number should start heading north once more, plus Atlanta and the USA should start contributing. 2016 turnover and profits look set rise as there will be a whole year of Select Pharma turnover and profits to be added together with increased cross selling opportunities gained by SBS access to Select Pharma clients and vice versa plus there are no shares left so any new institution wanting a meaningful stake will have to pay for it. SBS management, though I give them a hard time of it sometimes, are proving to be able to deliver the goods. Their acquisition choices are coming good, have been bought at decent prices , the way that they are gelling together and each new one is helping the rest shows the plan is working. Controlled growth by acquisition is the name of the game SBS Market Cap is now over £50m , this might attract some new Institutions that have minimum market cap limits set for investment purposes. Within 4 years I expect to see Turnover of £50m which will help to do the same In short , SBS is starting to look like it might be another ABC dyor |
Posted at 19/3/2015 21:42 by dyfiman Hello Buywell2 ............may I ask what your view is of SBS's current 'form' - how things are going on the ground....... ?? And is their a sporting chance that next Wednesday's final results will be good enough to get the share price moving ?? My uneducated view is that is seems a decent company in a good market spot with a decent set of people running affairs..... and some heavyweight investors. I'm also pleased that they include Mr Griffiths, a very successful and clever, serial investor. He's not in SBS just because he likes the nightlife in Nottingham !! Regards to you and any other SBS investors lurking out there. END |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
